The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

Respiratory viruses are continuing to spread across the United States and such activity "is expected to continue for several ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

Human Metapneumovirus (HMPV) is a respiratory virus that may not be on most folk’s radars, but it’s more common than you ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led ...

Rising flu cases hitting Toronto and Vancouver hardest, COVID rates declining and norovirus circulating more than usual ...